Latest Medtech News

Johnson & Johnson agreed to acquire medical-devices maker Shockwave Medical for a total enterprise value of about $13.1 billion.

Shockwave makes medical devices that treat cardiovascular diseases, particularly for calcified arterial lesions. In February, it projected revenue for 2024 in a range from $910 million to $930 million, which would be a roughly 27% increase from the previous year.

“The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets,” the company said.

The deal is Johnson & Johnson’s biggest since its $16.6 billion purchase of heart-device maker Abiomed, which it agreed to in November 2022.

Bain M&A Midyear Report 2024: "Strategic M&A has been steady over the past 12 months, with 2024 deal value expected to be on track to end slightly above 2023.
Healthcare remains a major catalyst for strategic M&A as companies seek to shore up top-line growth and optimize portfolios around therapeutic areas and technologies.
Overall deal value rose by 24% against an anemic early 2023 . Private equity (PE) and venture capital appear to have bottomed out and are starting to show improvement. Strategic deal valuations have moved up a bit, hinting that pricing may have seen a bottom. And taking a regional view, the Americas and Europe, the Middle East, and Africa are continuing to experience a return to dealmaking while Asia-Pacific is in the middle of another down year.
Companies are looking for cost and growth, not just one or the other. Dealmakers are adapting their M&A processes (from screening to diligence to integration) to meet changing environments. We see that ability in the current shift to targeting cost synergies in growth deals and growth synergies in cost deals. "